Clinicopathological and Prognostic Significance of C-Met Overexpression in Breast Cancer.

Xixi Zhao,Jingkun Qu,Yuxin Hui,Hong Zhang,Yuchen Sun,Xu Liu,Xiaoyao Zhao,Zitong Zhao,Qian Yang,Feidi Wang,Shuqun Zhang
DOI: https://doi.org/10.18632/oncotarget.18142
2017-01-01
Oncotarget
Abstract:BACKGROUND:c-Met has been shown to promote organ development and cancer progression in many cancers. However, clinicopathological and prognostic value of c-Met in breast cancer remains elusive.METHODS:PubMed and EMBASE databases were searched for eligible studies. Correlation of c-Met overexpression with survival data and clinicopathological features was analyzed by using hazard ratio (HR) or odds ratio (OR) and fixed-effect or random-effect model according to heterogeneity. All statistical tests were two-sided.RESULTS:32 studies with 8281 patients were analyzed in total. The c-Met overexpression was related to poor OS (overall survival) (HR=1.65 (1.328, 2.051)) of 18 studies with 4751 patients and poor RFS/DFS (relapse/disease free survival) (HR=1.53 (1.20, 1.95)) of 12 studies with 3598 patients. Subgroup analysis according to data source/methods/ethnicity showed c-Met overexpression was related to worse OS and RFS/DFS in Given by author group, all methods group and non-Asian group respectively. Besides, c-Met overexpression was associated with large tumor size, high histologic grade and metastasis.CONCLUSIONS:Our results showed that c-Met overexpression was connected with poor survival rates and malignant activities of cancer, including proliferation, migration and invasion, which highlighted the potential of c-Met as significant candidate biomarker to identify patients with breast cancer at high risk of tumor death.
What problem does this paper attempt to address?